Journal of Pharmacy and Pharmacology 1989-06-01

Disposition of the hypolipidaemic agent, 2,3-dihydrophthalazine-1,4-dione, in Sprague Dawley rats.

I H Hall, C B Oswald, S D Wyrick, J H Maguire, R P Shrewsbury

Index: J. Pharm. Pharmacol. 41(6) , 394-7, (1989)

Full Text: HTML

Abstract

The disposition of [14C]2,3-dihydrophthalazine-1,4-dione, a potent hypolipidaemic agent, has been determined after both intravenous and oral administration. Both the routes of administration afforded multi-exponential disposition with an estimated t1/2 of approximately 75 h. After oral administration, the drug was observed to be absorbed rapidly from the intestine and distributed quickly to all tissues of the body. A large quantity of the 14C-radioactivity was found in the skin and carcass. Approximately 35% of the administered radioactivity was excreted in urine after oral administration and 11% in the faeces. Approximately 66% of the radioactivity excreted in urine was the parent drug. There was evidence of an additional metabolite which accounted for 28% of the urinary radioactive excretion. The parent drug has little serum protein binding, is highly water soluble, and is probably taken up by cells by passive diffusion.


Related Compounds

Related Articles:

Effects of 2,3-dihydrophthalazine-1,4-dione on Sprague Dawley rats lipid metabolism and serum lipoproteins.

1988-01-01

[Biomed. Biochim. Acta 47(4-5) , 423-33, (1988)]

Anti-inflammatory activity of 2,3-dihydrophthalazine-1,4-diones in CF1 mice.

1996-01-01

[Int. J. Tissue React. 18(2-3) , 47-55, (1996)]

The anti-neoplastic activity of 2,3-dihydrophthalazine-1,4-dione and N-butyl-2,3-dihydrophthalazine-1,4-dione in human and murine tumor cells.

1992-02-01

[Anticancer Drugs 3(1) , 55-62, (1992)]

Differences in the reactivity of phthalic hydrazide and luminol with hydroxyl radicals.

1999-01-01

[Free Radic. Res. 30(1) , 45-57, (1999)]

More Articles...